Related Experiment Video

Updated: Mar 7, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights

Beibei Xu1, Dragana Lovre1, Franck Mauvais-Jarvis1

  • 1Department of Medicine, Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA, USA.

Journal of Diabetes and Its Complications
|February 11, 2017
PubMed

Insights

Selective estrogen receptor modulators (SERMs) impact metabolic homeostasis, obesity, and diabetes. This review explores their effects in rodent models and postmenopausal women, highlighting therapeutic potential.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Research

Background:

  • Selective estrogen receptor modulators (SERMs) exhibit tissue-specific estrogen receptor (ER) agonist/antagonist activities.
  • First-generation SERMs (e.g., Tamoxifen) treat ER-positive breast cancer; second-generation (e.g., Raloxifene) prevent osteoporosis.
  • Third-generation SERMs, like bazedoxifene (BZA), prevent osteoporosis with reduced estrogenic effects on breast and uterus, and BZA with conjugated estrogens (CE) is a novel menopausal treatment.

Purpose of the Study:

  • To summarize current knowledge on the effects of SERMs on metabolic homeostasis, obesity, and diabetes.
  • To review findings from both rodent models and postmenopausal women.
  • To highlight the growing interest in SERMs for managing metabolic disturbances associated with menopause.

Main Methods:

  • Literature review and synthesis of existing research.
  • Analysis of studies involving rodent models investigating SERM effects on metabolism.
  • Examination of clinical data from postmenopausal women assessing SERM impacts on metabolic parameters.

Main Results:

  • SERMs demonstrate varied effects on metabolic homeostasis, influencing parameters like glucose metabolism, lipid profiles, and body weight.
  • Rodent models show potential for SERMs in mitigating metabolic syndrome and type 2 diabetes.
  • Clinical studies in postmenopausal women suggest SERMs may favorably impact metabolic health, though effects can be complex and context-dependent.

Conclusions:

  • SERMs, particularly newer generations, show promise in addressing metabolic dysregulation associated with menopause.
  • Further research is warranted to fully elucidate the mechanisms and clinical utility of SERMs in metabolic disease prevention and treatment.
  • The tissue-specific actions of SERMs offer a potential therapeutic avenue for managing menopausal symptoms and associated metabolic comorbidities.
Keywords:
BazedoxifeneDiabetesEnergy metabolismMetabolic syndromeSelective estrogen receptor modulatorsSteatosis

More Related Videos

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas03:02

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

437
A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

16.3K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
769
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.0K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
567